Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAWH Ascend Wellness	$0.65 +2.5%	$0.38	$0.26 ▼ $1.23	$131.87M	1.04	132,329 shs	631,903 shs
ESPR Esperion Therapeutics	$1.94 +8.4%	$1.29	$0.69 ▼ $3.94	$354.78M	0.82	6.06 million shs	9.26 million shs
FULC Fulcrum Therapeutics	$6.85 +4.7%	$7.15	$2.32 ▼ $10.13	$353.76M	2.47	982,387 shs	307,425 shs
VIGL Vigil Neuroscience	$8.05	$7.99	$1.31 ▼ $8.10	$383.91M	3.33	1.09 million shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAWH Ascend Wellness	-8.80%	+36.80%	+62.61%	+90.24%	-38.90%
ESPR Esperion Therapeutics	-2.98%	+10.49%	+50.42%	+145.21%	-2.72%
FULC Fulcrum Therapeutics	+3.15%	-4.94%	-16.48%	+16.16%	-27.41%
VIGL Vigil Neuroscience	0.00%	-0.25%	0.00%	+239.66%	+162.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAWH Ascend Wellness	2.0641 of 5 stars	0.0	5.0	0.0	2.5	1.7	1.3
ESPR Esperion Therapeutics	4.2602 of 5 stars	3.4	3.0	3.9	3.3	1.7	0.6
FULC Fulcrum Therapeutics	1.9732 of 5 stars	3.3	3.0	0.0	1.8	1.7	0.0
VIGL Vigil Neuroscience	3.4263 of 5 stars	4.0	3.0	0.0	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAWH Ascend Wellness	0.00	N/A	N/A	N/A
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	260.82% Upside
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	10.53% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	34.16% Upside

Current Analyst Ratings Breakdown

Latest AAWH, VIGL, ESPR, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAWH Ascend Wellness	$518.59M	0.25	$0.10 per share	6.64	$0.69 per share	0.93
ESPR Esperion Therapeutics	$268.13M	1.43	$0.03 per share	76.79	($1.97) per share	-0.98
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAWH Ascend Wellness	-$48.21M	-$0.42	N/A	N/A	N/A	-15.47%	-72.18%	-9.55%	N/A
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.84%	N/A
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	N/A

Latest AAWH, VIGL, ESPR, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAWH Ascend Wellness	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAWH Ascend Wellness	2.61	1.47	0.80
ESPR Esperion Therapeutics	N/A	1.18	0.81
FULC Fulcrum Therapeutics	N/A	24.42	24.42
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAWH Ascend Wellness	17.31%
ESPR Esperion Therapeutics	47.39%
FULC Fulcrum Therapeutics	89.83%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
AAWH Ascend Wellness	22.38%
ESPR Esperion Therapeutics	1.70%
FULC Fulcrum Therapeutics	7.00%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAWH Ascend Wellness	2,300	204.44 million	166.44 million	Not Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable
VIGL Vigil Neuroscience	40	47.69 million	39.10 million	Not Optionable

AAWH, VIGL, ESPR, and FULC Headlines

Recent News About These Companies

Vigil Neuroscience Inc Merger and Leadership Changes

August 13 at 5:51 AM | theglobeandmail.com

Blair William & Co. IL Raises Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

August 10 at 4:18 AM | marketbeat.com

Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $10.80

August 9, 2025 | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Average Recommendation of "Hold" from Brokerages

August 6, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Significant Growth in Short Interest

August 3, 2025 | marketbeat.com

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

July 14, 2025 | businesswire.com

Vigil Neuroscience, Inc. (VIGL) Cash Flow - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq

June 27, 2025 | nasdaq.com

Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?

June 25, 2025 | zacks.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.comB

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.comM

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.comT

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright & Co. Downgrades Vigil Neuroscience (VIGL)

May 28, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AAWH, VIGL, ESPR, and FULC Company Descriptions

Ascend Wellness OTC:AAWH

$0.64 +0.02 (+2.49%)

As of 03:57 PM Eastern

Ascend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.

Esperion Therapeutics NASDAQ:ESPR

$1.94 +0.15 (+8.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 0.00 (0.00%)

As of 07:56 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Fulcrum Therapeutics NASDAQ:FULC

$6.85 +0.31 (+4.74%)

Closing price 04:00 PM Eastern

Extended Trading

$6.74 -0.11 (-1.59%)

As of 06:45 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vigil Neuroscience NASDAQ:VIGL

$8.05 0.00 (0.00%)

As of 08/5/2025

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time